T-2307 是一种芳基脒，在体外和体内具有抗真菌活性。T-2307 具有广谱抗菌活性，包括念珠菌属 (Candida， MIC 为 0.00025 至 0.0078 μg/mL)、新型隐球菌属 (Cryptococcus neoformans，MIC 为 0.0039-0.0625 μg/mL) 和曲霉属 (Aspergillus；MIC 为 0.0156-4 μg/mL)。
货号:ajcx36140
CAS:873546-31-7
分子式:C25H35N5O2
分子量：437.58
溶解度:DMSO : 50 mg/mL (114.26 mM; ultrasonic and adjust pH to 3 with HCl)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

T-2307, an arylamidine, has antifungal activities in vitro and in vivo. T-2307 exhibits broad-spectrum activity against clinically significant pathogens, including Candida species (MIC range, 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range, 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range, 0.0156 to 4 μg/mL) [1].

T-2307 exhibits potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent Candida albicans strains as well as against azole-susceptible strains[1]. T-2307 shows efficacy in a murine model of candida glabrata infection despite in vitro trailing growth phenomena[2].

In mouse models of disseminated candidiasis, cryptococcosis, and aspergillosis, the ED50 of T-2307 were 0.00755, 0.117, and 0.391 mg/kg, respectively[1].

[1]. Junichi Mitsuyama, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008 Apr;52(4):1318-24.
[2]. Eio Yamada, et al. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother. 2010 Sep;54(9):3630-4.